x

Anebulo Pharmaceuticals, Inc. (Nasdaq:ANEB)

Health Care/Life Sciences • Pharmaceuticals
CIK 1815974
Company

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. Its product candidate, Selonabant, is a small molecule antagonist of cannabinoid binding receptor type-1. The company was founded by Joseph F. Lawler on April 23, 2020 and is headquartered in Lakeway, TX.

Address
1017 Ranch Road 620 South
Suite 107
Lakeway, Texas 78734
Employees
3
Stock Info
Close
$1.0500
Day Range
1.0100 - 1.0816
52 Week Range
0.8001 - 3.3000
Average volume
29.03K
Short Interest
66.89K (02/14/25)
% of Float Shorted
0.27%
Market Cap
$42.32M
Revenue
N/A
Net Income
-$8.2M
2020 Sales Growth
N/A
Rev. per Employee
N/A
P/E Ratio
N/A
EPS
-$0.2905
Yield
N/A
Dividend
N/A
Ex-Dividend Date
N/A
Key Executives
Board Of Directors
Chairman
Joseph F. Lawler
Chief Executive Officer & Director
Richard Anthony Cunningham
Independent Director
Bimal R. Shah
Independent Director
Nathaniel Calloway
Independent Director
Kenneth S. Lin
Independent Director
Areta Kupchyk
Independent Director
Jason M. Aryeh
Independent Director
Aron R. English
SEC filings
DateFormEvent
10 Dec, 2024 4
13 Nov, 2024 10-Q
13 Nov, 2024 8-K
17 Oct, 2024 8-K
25 Sep, 2024 8-K
25 Sep, 2024 10-K
22 Jul, 2024 8-K
17 Jun, 2024 8-K
17 Jun, 2024 4
17 Jun, 2024 4
17 Jun, 2024 4
17 Jun, 2024 4
17 Jun, 2024 4
17 Jun, 2024 4
17 Jun, 2024 4
15 May, 2024 10-Q
15 May, 2024 8-K
8 Mar, 2024 4/A
1 Mar, 2024 4
13 Feb, 2024 8-K
13 Feb, 2024 10-Q
20 Dec, 2023 4
21 Nov, 2023 8-K
14 Nov, 2023 10-Q
14 Nov, 2023 8-K
30 Oct, 2023 DEF 14A
30 Oct, 2023 ARS
19 Oct, 2023 PRE 14A
11 Oct, 2023 4
11 Oct, 2023 3
10 Oct, 2023 4
10 Oct, 2023 3
6 Oct, 2023 8-K CEO Change
2 Oct, 2023 3
29 Sep, 2023 8-K
22 Sep, 2023 10-K
20 Sep, 2023 8-K
5 Sep, 2023 8-K
11 May, 2023 8-K
11 May, 2023 10-Q
11 Apr, 2023 8-K
4 Apr, 2023 3
28 Mar, 2023 8-K
8 Mar, 2023 8-K
10 Feb, 2023 8-K
10 Feb, 2023 10-Q
9 Jan, 2023 8-K
13 Dec, 2022 4
13 Dec, 2022 4
10 Nov, 2022 EFFECT
10 Nov, 2022 8-K
10 Nov, 2022 10-Q
8 Nov, 2022 CORRESP
8 Nov, 2022 UPLOAD
2 Nov, 2022 3
2 Nov, 2022 S-1
2 Nov, 2022 4
28 Oct, 2022 8-K
25 Oct, 2022 DEFR14A
17 Oct, 2022 DEF 14A
13 Oct, 2022 8-K
11 Oct, 2022 D
4 Oct, 2022 4
4 Oct, 2022 4
3 Oct, 2022 4
3 Oct, 2022 4
3 Oct, 2022 4
3 Oct, 2022 4
30 Sep, 2022 4
29 Sep, 2022 8-K
26 Sep, 2022 8-K
9 Sep, 2022 8-K
9 Sep, 2022 10-K
5 Jul, 2022 8-K
7 Jun, 2022 4
24 May, 2022 3
24 May, 2022 8-K
11 May, 2022 8-K
11 May, 2022 10-Q
22 Apr, 2022 S-8
1 Apr, 2022 8-K
11 Feb, 2022 10-Q
11 Feb, 2022 8-K
7 Feb, 2022 4
7 Feb, 2022 3
5 Jan, 2022 8-K CEO Change
3 Jan, 2022 8-K
21 Dec, 2021 4
16 Dec, 2021 4
3 Dec, 2021 4
3 Dec, 2021 4
16 Nov, 2021 8-K
12 Nov, 2021 10-Q
12 Nov, 2021 8-K
22 Sep, 2021 10-K
22 Sep, 2021 DEFA14A
22 Sep, 2021 8-K
22 Sep, 2021 DEF 14A
21 Jun, 2021 10-Q
17 May, 2021 4/A
17 May, 2021 SC 13D
10 May, 2021 424B4 IPO completed
7 May, 2021 4
7 May, 2021 CERT
6 May, 2021 3
6 May, 2021 EFFECT
6 May, 2021 3
6 May, 2021 3
6 May, 2021 3
6 May, 2021 3
6 May, 2021 3
6 May, 2021 3
6 May, 2021 3
5 May, 2021 CORRESP
5 May, 2021 8-A12B
5 May, 2021 S-1/A
5 May, 2021 CORRESP
5 May, 2021 CORRESP
4 May, 2021 UPLOAD
26 Apr, 2021 FWP
26 Apr, 2021 S-1/A
26 Apr, 2021 CORRESP
15 Apr, 2021 UPLOAD
1 Apr, 2021 CORRESP
1 Apr, 2021 S-1
25 Mar, 2021 UPLOAD
12 Mar, 2021 DRS/A
11 Mar, 2021 DRSLTR
26 Feb, 2021 UPLOAD
29 Jan, 2021 DRSLTR
29 Jan, 2021 DRS
Last update:2025-03-06 13:23:20.554548
Anebulo Pharmaceuticals, Inc. by TradingView

Sign Up to Subscribe